Lupin FDA Inspection, Prompt Response

  Published 7 months ago

FDA inspection of Lupin (Sep 29, Oct 10, 2025) yielded one observation; Lupin will promptly respond within the regulatory timeline.

  • Inspection spanned two weeks, concluding on October 10, 2025, with a single regulatory observation noted.
  • Lupin pledges to address the FDA’s findings promptly, ensuring compliance across its global pharmaceutical operations worldwide.
  • The company, headquartered in Mumbai, distributes generic, complex, biotech products, and APIs to over 100 markets.

You might like these

Kotak Bank Q1 Profit Falls 47%

RBI Extends Financial Market Trading Hours

Jindal Steel Launches Advanced Galvanising Line in Odisha

Bajel Projects Stock Surges 5% on Mega Power Order

RVNL Wins OHE Upgrade Contract

Kalpataru Wins Global T&D & B&F Orders

Natco Pharma Up 3.3% After Court Ruling

News that matters the most ⚡